On March 14 2022, The Nektar Therapeutics (NASDAQ: NKTR) announced that a review by an independent Data Monitoring Committee (DMC) evaluating the safety and efficacy of bempegaldesleukin in combination with Opdivo (nivolumab), revealed that the study has failed to meet the primary endpoints of progression-free...
Gritstone Bio, Inc. (NASDAQ: GRTS), formerly known as Gritstone Oncology, is a clinical-stage biotechnology company developing targeted immunotherapies for a range of diseases in the cancer and infectious disease space. The Company’s approach is based on leveraging the inherent abilities of the immune system to...
Alzheimer’s is the sixth leading cause of death in the U.S, a disease that causes irreversible degeneration of the brain cells and affects a person’s cognitive and behavioral abilities such as impaired judgment, deteriorating memory and personality changes with the gradual loss of motor abilities...
